Related Experiment Video

Updated: Jun 13, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Genetic variants of the Renin Angiotensin system: effects on atherosclerosis in experimental models and humans

Alan Daugherty1, Aruna Poduri, Xiaofeng Chen

  • 1Saha Cardiovascular Research Center, University of Kentucky, BBSRB, Room B-243, Lexington, KY 40536-0509, USA. Alan.Daugherty@uky.edu

Current Atherosclerosis Reports
|April 29, 2010
PubMed

Insights

The renin-angiotensin system (RAS) influences atherosclerosis. While angiotensin II is key, other peptides and receptors are involved. Genetic studies are needed to clarify RAS

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Genetics

Background:

  • The renin-angiotensin system (RAS) significantly impacts atherosclerosis development, particularly in animal models.
  • Angiotensin II was historically viewed as the primary RAS effector, but numerous other bioactive peptides and their receptors are now recognized.
  • The role of genetic manipulation within the RAS pathway in atherosclerosis remains incompletely understood.

Purpose of the Study:

  • To review the current understanding of the renin-angiotensin system's role in atherosclerosis.
  • To highlight the impact of genetic variations in RAS components on disease development.
  • To identify knowledge gaps and suggest future research directions.

Main Methods:

  • Review of existing literature on the renin-angiotensin system and atherosclerosis.
  • Analysis of experimental studies involving genetic interruption of RAS peptide synthesis.
  • Examination of studies investigating the role of RAS receptors, specifically AT1a, in atherosclerosis.
  • Evaluation of human genetic studies linking RAS receptor variants to atherosclerotic diseases.

Main Results:

  • Genetic interruption of RAS peptide synthesis shows promise in reducing experimental atherosclerosis, though human data is inconsistent.
  • AT1a receptors are critically involved in experimental atherosclerosis.
  • Limited studies connect genetic variants of angiotensin II receptors to human atherosclerotic conditions.

Conclusions:

  • The renin-angiotensin system plays a complex role in atherosclerosis.
  • Further genetic studies are essential to fully elucidate the involvement of RAS in human atherosclerotic diseases.
  • Targeting specific RAS components or receptors may offer therapeutic potential.

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...